clinical trial · NCT00032773
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
Astex Pharmaceuticals, Inc.·phase2·terminated·n = 36
Acute Graft Versus Host Diseasepentostatin for injection
brief summary
To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while producing treatment failure (defines as death, grade 3/4 toxicity, or progressive disease) in 40% or less of patients.
started
Jan 30, 2002
primary completion
Nov 3, 2005
completion
Nov 3, 2005
last updated
Aug 2, 2024
official title
A Sequentially Adaptive, Open Label, Dose-finding, Phase I/II Trial of Pentostatin in the Treatment of Steroid-refractory Acute Graft Versus Host Disease (aGvHD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol